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Purpose: Many women with X chromosome aneuploidy undergo
lifetime clinical monitoring for possible complications. However,
ascertainment of cases in the clinic may mean that the penetrance
has been overestimated.
Methods: We characterized the prevalence and phenotypic
consequences of X chromosome aneuploidy in a population of
244,848 women over 40 years of age from UK Biobank, using
single-nucleotide polymorphism (SNP) array data.
Results: We detected 30 women with 45,X; 186 with mosaic 45,X/
46,XX; and 110 with 47,XXX. The prevalence of nonmosaic 45,X
(12/100,000) and 47,XXX (45/100,000) was lower than expected,
but was higher for mosaic 45,X/46,XX (76/100,000). The char-
acteristics of women with 45,X were consistent with the
characteristics of a clinically recognized Turner syndrome pheno-
type, including short stature and primary amenorrhea. In contrast,
women with mosaic 45,X/46,XX were less short, had a normal
reproductive lifespan and birth rate, and no reported cardiovascular
complications. The phenotype of women with 47,XXX included
taller stature (5.3 cm; SD = 5.52 cm; P = 5.8 × 10−20) and earlier
menopause age (5.12 years; SD = 5.1 years; P = 1.2 × 10−14).
Conclusion: Our results suggest that the clinical management of
women with 45,X/46,XX mosaicism should be minimal, particularly
those identified incidentally.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-
0271-6
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INTRODUCTION
X chromosome aneuploidy is a common chromosome
abnormality.1 It can be difficult to determine the clinical
importance of X chromosome aneuploidy because population-
based studies have been limited to tens of individuals
ascertained from prenatal screening and without long-term
follow up into older age.2–4 Cohorts recruited through clinical
features may be affected by ascertainment bias, because only
individuals with syndromic features are being tested. It is
increasingly important to determine the phenotypic conse-
quences of genetic abnormalities in nonclinical populations as
more genomic testing is carried out on individuals in the
general population, including direct-to-consumer testing.5
Women with trisomy X (47,XXX) are reported to be taller
than average and to have earlier menopause, but the evidence to
support these associations is limited to potentially biased
collections of cases reaching medical attention.6 In contrast,
women with a 45,X chromosome complement or Turner
syndrome are generally short (20 cm below population mean),
may have physical features such as a webbed neck, and about
80% have primary amenorrhea.7 Women with Turner syn-
drome are at an increased risk of hearing difficulties and cardiac
disorders, particularly dissection of the aorta.8–11 Hypergonado-
trophic hypogonadism in Turner syndrome means that
pregnancy is often difficult to achieve spontaneously, but if
achieved, pregnancies are considered high risk, predominantly
due to an increased risk of cardiac complications.12
In this study, we tested over 244,000 women from the UK
Biobank, a population-based study of adults aged 40–70,
for X chromosome aneuploidy using single-nucleotide poly-
morphism (SNP) array data and identified 326 individuals with
whole X chromosome imbalances. The availability of such a
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large population sample allowed us to characterize the
phenotypic characteristics, including adult diseases, of women
with X chromosome aneuploidy in a nonclinical context.
MATERIALS AND METHODS
UK Biobank cohort
UK Biobank recruited over 500,000 individuals aged 37–73
years (99.5% were between 40 and 69 years) between 2006
and 2010 from across the United Kingdom. Participants
provided a range of information via questionnaires and
interviews (e.g., demographics, health status, lifestyle,
anthropometric measurements).13 SNP genotypes were
generated from the Affymetrix Axiom UK Biobank array
(~450,000 individuals) and the UK BiLEVE array (~50,000
individuals). This data set underwent extensive central
quality control (http://biobank.ctsu.ox.ac.uk) resulting in
244,848 females of white European descent included in
subsequent analyses. Basic characteristics for these women
are given in Supplemental Table S1. Our study was carried
out using UK Biobank, which is covered by its own ethical
review process. Details of patient/public involvement and
ethical governance in the UK Biobank are available
online (http://www.ukbiobank.ac.uk/about-biobank-uk/ and
https://www.ukbiobank.ac.uk/wp-content/uploads/2011/07/
Summary-EGF-consultation.pdf?phpMyAdmin=trmKQlYdjj
nQIgJ%2CfAzikMhEnx6).
Identification of women with chromosome X aneuploidy
Log R ratio (LRR) and B-allele frequency (BAF) values for 18,725
nonpseudoautosomal, chromosome X SNP probe sets were
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Fig. 1 Exemplar log R ratio (LRR) and B-allele frequency (BAF) plots for each detected X chromosome state. (a,b) Respective LRR and BAF for a
>80% dosage 45,X individual. (c,d) LRR and BAF for a mosaic (≤80%) dosage 45,X/46,XX individual respectively. (e,f) Respective LRR and BAF of a 46,XX
individual. (g,h) Respective LRR and BAF of a 47,XXX individual. Finally for comparison, plots (i) and (j) represent the respective LRR and BAF of a 46,XY male
illustrating a similar LRR dosage to 45,X; note the 4.5-Mb 2-copy dosage region at 88.5 Mb on chromosome X, which is homologous to the Y chromosome
present in all males (PAR3)
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provided by UK Biobank. For each female, we calculated the
mean LRR, and the number of probe sets falling inside the
expected BAF heterozygous range (values between 0.49 and 0.51).
We classified females as having X chromosome aneuploidy if
they were outliers in both the cohort mean LRR distribution and
the expected heterozygous BAF count distribution (Supplemental
Fig. S1). Outliers for both mean LRR and BAF heterozygote
count were defined as more than 1.5 times the interquartile
range away from the mean.14 We visually inspected the
distribution of chromosome-wide LRR and BAF to ensure
aneuploidy was consistent along the full X chromosome only
(Fig. 1, Supplemental Figs. S2–S4). The method was validated
in a series of Turner syndrome cases tested by cytogenetics
(see Supplemental Methods and Supplemental Fig. S5).
In females with chromosome X loss, the percentage of
mosaicism was estimated by dividing individual mean LRR by
the lowest observed mean LRR across all individuals, giving a
“dosage” of 45,X cells. We defined females with chromosome
X loss as mosaic 45,X/46,XX if the dosage was ≤80% and as
nonmosaic 45,X if the dosage was >80%. We chose 80%
mosaicism relatively arbitrarily, but it corresponded to the
cytogenetic validation data (Supplementary Methods) and all
but one of the individuals with hospital episode statistics
(HES) records of Turner syndrome, detected by our method,
had a dosage >80%. For the 186 women we classified as
mosaic 45,X/46,XX, the estimated percentage of 45,X cells per
sample ranged from 15 to 79%.
Association testing for a range of phenotypes
We tested the association of X chromosome aneuploidy with a
range of phenotypes and traits including anthropometric,
reproductive, cardiovascular, learning/memory, and incidence
of various diseases (Supplemental Table S1). X chromosome
aneuploidy was stratified into three groups: 45,X nonmosaic
samples, 45,X/46,XX mosaic samples, and 47,XXX samples.
Controls were all other women in UK Biobank (max N =
244,522). We used linear regression models in STATA 13,
adjusting for SNP chip type (UKB Axiom or UK BiLEVE),
ancestry-principal components 1 to 5 supplied by UK
Biobank, test center, and age. Hypertension and hypothyroid-
ism were tested using logistic regression and household
income was tested using ordinal logistic regression. Variables
were inverse normalized to account for skewed distributions.
RESULTS
Detection of chromosome X aneuploidy
We detected 326 women with whole X chromosome
imbalances among the 244,848 women from the UK Biobank,
110 with a higher dosage indicating an additional X
chromosome and 216 with a lower dosage, suggesting only
one X chromosome in some or all cells (Fig. 1 and
Supplemental Figs. S2–S4). Of the 216 suspected 45,X women
there was a range of estimated dosages with mean LRRs
ranging from –0.5 to –0.07 (mean = –0.23). Of these women,
30 had an estimated X chromosome dosage in the lowest
quintile, suggesting the majority of cells had only one X,
consistent with a 45,X karyotype. The prevalence of 45,X was
therefore 12/100,000 women. Our classification of 186 women
with a dosage ≤ 80% as mosaic gives a prevalence of 76/
100,000 women with mosaic 45,X/46,XX in UK Biobank.
Detection of 45,X and 45,X/46,XX mosaicism compared
with hospital record data
No women self-reported having Turner syndrome at their
baseline visit. There are no general practitioner (GP) records, no
links to clinical genetics registries, and only in-patient hospital
record (HES) data for 78% of UK Biobank participants at the
time of analysis. Of the 30 women we classified with nonmosaic
45,X, 29 had HES data available, of whom 16 had an ICD-10
code for Turner syndrome (55%). This left 13 individuals who
had had an overnight hospital stay, but Turner syndrome was
not recorded in HES (Supplemental Fig. S6). Of the 186 women
we classified as having mosaic 45,X/46,XX only one (0.5%)
had a HES record of “Turner syndrome,” and she had an
estimated X chromosome loss of 77.5%, close to our cutoff of
80% for nonmosaic 45,X.
In addition to the 216 women we characterized with SNP
array data as 45,X nonmosaic or 45,X/46,XX mosaic, 7 women
had a HES record of either “Turner syndrome” (n = 5) or
“Mosaicism 45,X/46,XX” (n = 2). Of the five women with a
HES record of nonmosaic “Turner syndrome,” two were not
outliers for whole X chromosome dosage, but on inspection of
SNP intensity and BAF data, they had a deletion of the p arm
and duplication of the q arm, suggesting 46,X,i(Xq) (iso-
chromosome Xq) (Supplemental Fig. S7); and three were not
detected by the SNP array method because their SNP array
metrics were well within the normal range. The two women
with a HES record of “Mosaicism 45,X/46,XX” both had a
normal 46,XX array profile. These samples were either below
the limit of detection or could represent age-related loss of the
X, which is not detected by our array method.
Detection of partial X chromosome deletion and
isochromosome Xq
After detecting that some women with HES records of “Turner
syndrome” had a likely isochromosome Xq, we reanalyzed the
data separately for the X chromosome p and q arms to detect
additional cases with X chromosome abnormality causing
Turner syndrome. We identified a total of five potential 46,X,i
(Xq) cases, including the two that had a “Turner syndrome”
ICD-10 code (Supplemental Fig. S8). This protocol modifica-
tion also identified nine women with an X chromosome
deletion of between 15 and 55 megabases in size (Supple-
mental Fig. S9). The 14 women with partial deletions and 46,
X,i(Xq) were of shorter stature (Supplemental Table S2).
45,X and 45,X/46,XX mosaicism and height
The 30 women with evidence of nonmosaic 45,X chromo-
some loss were on average 17.2 cm shorter than 46,XX
females (Tables 1 and 2, Fig. 2, Supplemental Table S3). In
contrast, the 186 mosaic 45,X/46,XX cases were on average
only 3.8 cm shorter than 46,XX women (P = 4.0 × 10−14).
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Height ranged from 139 to 182 cm in the mosaic group, and
7% of these women were taller than one standard deviation
above the mean height in 46,XX women. There was a weak
correlation between percentage mosaicism and height in the
women with mosaic 45,X/46,XX (r = 0.23).
45,X and 45,X/46,XX mosaicism and ovarian function
Primary amenorrhea was not specifically coded in UK
Biobank, but 16/30 women with nonmosaic 45,X answered
“don’t know” or “prefer not to answer” to the question “How
old were you when your periods started?”. This proportion
(53%) was much higher than that in 46,XX women (2.9%)
and we assume most of these women did not go through
menarche. For the other 14 women with nonmosaic 45,X,
menarche ages between 12 and 19 years were recorded. In
contrast, only 9 of the 186 women with mosaic 45,X/46,XX
did not report an age at menarche, and the mean menarche
timing was 13.2 years in those 177 individuals who recorded
Table 1 Characteristics of UK Biobank females stratified by X chromosome aneuploidy status
Trait Status N Included N Missing Mean SD Min. value Max. value
Age at recruitment (years) 45,X 30 0 54.84 7.77 42 69
45,X/46,XX 186 0 59.69 8.00 42 70
46,XX 244,522 0 57.09 7.94 40 71
47,XXX 110 0 56.83 7.06 41 69
Height (cm) 45,X 30 0 145.47 5.72 134.5 159
45,X/46,XX 186 0 158.89 7.52 139 182
46,XX 244,037 485 162.66 6.23 121 199
47,XXX 110 0 167.98 5.52 156 181
Menarche age (years) 45,X 14 16 15.36 2.59 12 19
45,X/46,XX 177 9 13.15 1.61 9 18
46,XX 237,744 6778 12.96 1.61 5 25
47,XXX 104 6 12.73 1.96 7 17
Natural menopause age (years) 45,X 5 25 45.40 6.43 37 51
45,X/46,XX 95 91 50.58 5.35 25 59
46,XX 108,479 136,043 50.02 4.53 18 65
47,XXX 60 50 44.90 5.10 32 56
Number of pregnancies 45,X 29 1 0.24 0.64 0 2
45,X/46,XX 186 0 2.22 1.75 0 10
46,XX 240,046 4476 2.30 1.58 0 31
47,XXX 107 3 1.93 1.77 0 10
Fluid intelligence score (0–13) 45,X 11 19 5.82 1.94 3 9
45,X/46,XX 79 107 5.99 2.32 2 12
46,XX 118,776 125,746 5.80 2.04 0 13
47,XXX 51 59 4.39 1.72 1 8
Household income category (1–5) 45,X 21 9 2.24 1.18 1 5
45,X/46,XX 156 30 2.28 1.17 1 5
46,XX 203,115 41,407 2.53 1.18 1 5
47,XXX 78 32 1.50 0.75 1 4
Townsend deprivation index 45,X 30 0 −1.32 2.54 −6.11 5.70
45,X/46,XX 186 0 −1.26 2.89 −5.39 6.71
46,XX 244,238 284 −1.51 2.93 −6.26 11.00
47,XXX 110 0 −0.54 3.38 −5.95 6.81
Birth weight (kg) 45,X 14 9 3.07 0.28 2.72 3.40
45,X/46,XX 89 77 3.36 0.40 2.55 4.28
46,XX 130,961 92,844 3.35 0.42 2.5 4.5
47,XXX 56 54 3.27 0.45 2.55 4.37
Body mass index (kg/m2) 45,X 30 0 27.19 4.30 18.36 35.94
45,X/46,XX 185 1 26.70 4.97 18.64 46.25
46,XX 243,502 1020 27.02 5.14 12.12 74.68
47,XXX 110 0 29.18 5.48 17.86 46.48
“45,X” are individuals assumed to be nonmosaic Turner syndrome individuals. “45,X/46,XX” are individuals assumed to be mosaic Turner syndrome. “46,XX” are con-
trols, and “47,XXX” are trisomy X individuals. Sixteen and 25 nonmosaic 45,X cases did not report menarche or menopause ages respectively
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Table 2 Association between X chromosome aneuploidy
and nine phenotypes
Trait Status N Effect
(SD)
Low
95% CI
(SD)
High
95% CI
(SD)
P
Height (cm) 45,X 30 −2.73 −3.07 −2.38 1.5 ×
10−53
45,X/
46,XX
186 −0.54 −0.68 −0.40 4.0 ×
10−14
47,
XXX
110 0.84 0.66 1.03 5.8 ×
10−20
Menarche age
(years)
45,X 14 1.33 0.81 1.86 5.9 ×
10−7
45,X/
46,XX
177 0.12 −0.03 0.26 0.12
47,
XXX
104 −0.15 −0.34 0.05 0.14
Natural
menopause
age (years)
45,X 5 −0.99 −1.86 −0.13 0.024
45,X/
46,XX
95 0.12 −0.08 0.32 0.23
47,
XXX
60 −0.98 −1.23 −0.73 1.2 ×
10−14
Number of
pregnancies
45,X 29 −1.50 −1.86 −1.14 3.3 ×
10−16
45,X/
46,XX
186 −0.12 −0.27 0.02 0.09
47,
XXX
107 −0.26 −0.44 −0.07 0.0076
Fluid
intelligence
score (0–13)
45,X 11 −0.17 −0.74 0.39 0.55
45,X/
46,XX
79 0.09 −0.12 0.30 0.39
47,
XXX
51 −0.74 −1.00 −0.48 3.7 ×
10−8
Household
income
category (1–5)
45,X 21 −0.89 −1.66 −0.12 0.024
45,X/
46,XX
156 −0.21 −0.51 0.08 0.15
47,
XXX
78 −1.98 −2.45 −1.51 8.7 ×
10−17
Townsend
deprivation
index
45,X 30 0.13 −0.20 0.47 0.43
45,X/
46,XX
186 0.13 0.00 0.27 0.052
47,
XXX
110 0.24 0.07 0.42 0.0067
Birth weight
(kg)
45,X 13 −0.67 −1.19 −0.14 0.013
89 0.02 −0.19 0.23 0.86
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Fig. 2 Relationship between chromosome X dosage in 45, X and 47,
XXX females for two quantitative traits. (a) Shows the height of 45, X
and 47, XXX females in UK Biobank and (b) Shows the natural menopause
age 45, X and 47, XXX females in UK Biobank. X chromosome dosage is
color coded (see key) for each category tested in the analysis. Distribution of
each trait in controls is shown in gray histogram for (a) height and (b)
natural menopause age
Table 2 continued
Trait Status N Effect
(SD)
Low
95% CI
(SD)
High
95% CI
(SD)
P
45,X/
46,XX
47,
XXX
56 −0.21 −0.47 0.05 0.11
Body mass
index (kg/m2)
45,X 30 0.13 −0.26 0.51 0.51
45,X/
46,XX
185 −0.09 −0.25 0.06 0.23
47,
XXX
110 0.46 0.26 0.66 6.3 ×
10−6
CI confidence interval.
The effect of the aneuploidy on each trait is given in number of standard devia-
tions change compared with 46,XX women, with an association P value. P values
that pass the threshold for statistical confidence, corrected for multiple testing,
are highlighted (i.e., equivalent to P < 0.05)
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an age, not different from the mean age of 12.95 years in the
46,XX women (P = 0.12).
The recruitment ages of the 30 women with nonmosaic 45,
X ranged from 42 to 69 years, but only 5 reported a natural
menopause age and the odds ratio (OR) for not reporting an
age at natural menopause compared with women with 46,XX
was 3.98 (95% confidence interval [CI] = 1.50, 13.31; P =
0.0026). Ninety-five of the 45,X/46,XX mosaic women
reported an age at natural menopause (Tables 1 and 2, Fig. 2,
Supplemental Table S3), at an average age of 50.6 years (range
= 25–59 years), again not different from the mean age in
control women with 46,XX (mean = 50 years; range = 18–65;
P = 0.23).
Only 4 of the 30 nonmosaic 45,X cases had ever been
pregnant, much fewer than in the remaining 46,XX women
with an odds ratio for never being pregnant of 32.35 (95% CI
= 11.21, 127.22; P = 8.98 × 10−17). Most of the mosaic 45,X/
46,XX cases reported a pregnancy, with only 37 of 186
reporting they had never been pregnant, a frequency not
different from women with 46,XX. The mean number of
pregnancies in the 45,X/46,XX women was 2.2, not different
from the control 46,XX individuals (P = 0.09). There was also
no increased incidence of pregnancy loss in the women with
45,X/46,XX, either from miscarriage, termination, or stillbirth.
45,X and 45,X/46,XX mosaicism and cardiac function
Heart defects are a common reported feature of Turner
syndrome, but we found few cases of heart defects in 45,X
women, based on self-report and ICD-10 codes. Four of the
30 women with 45,X had a medically diagnosed heart
condition, including coarctation/dissection of the aorta and
myocardial infarction. Blood pressure and hypertension risk
were elevated (e.g., hypertension OR = 3.15; 95% CI = 1.41,
6.99; P = 0.005), and arterial elasticity was 1.05 indices lower
in the 30 nonmosaic 45,X women (se = 0.32; P = 0.001) and
13 were on blood pressure medication (OR = 3.66; 95% CI =
0.93, 32.08; P = 7.7 × 10−4). Hypertension and blood pressure
were not raised in the mosaic 45,X/46,XX women (hyperten-
sion OR = 1.02; 95% CI = 0.75, 1.40; P = 0.88) (Table 3), The
women with mosaic 45,X/46,XX had not had more cardiac
operations and were not more likely to be on blood pressure
medication than the 46,XX women.
Trisomy X phenotype
Trisomy X was detected in 110 women, giving a prevalence of
45/100,000 in UK Biobank women. A further two cases
appeared to be mosaic 46,XX/47,XXX, but were excluded
from further analyses because there were too few in this
category to analyze separately. Of the 110 47,XXX women, 90
were present in the HES records, but none had a prior
diagnosis of “Karyotype 47,XXX” as determined by ICD-10
code.
We found an association between trisomy X and adult
height (ß = 0.84 SDs; 95% CI = 0.66, 1.03; P = 5.8 × 10−20).
Women with 47,XXX were 5.3 cm taller on average than 46,
XX women (Fig. 2, Tables 1 and 2, Supplemental Table S3).
Women with trisomy X had normal age at menarche, but an
average 5.12 years earlier age of natural menopause (ß = -0.98
SDs; 95% CI = -1.23, -–0.73; P = 1.2 × 10−14) (Tables 1 and
2, Fig. 2, Supplemental Table S3). Women with 47,XXX had a
similar number of pregnancies (mean = 1.9, range 0–10) and
no higher frequency of pregnancy loss than 46,XX controls.
We also found that women with trisomy X had a lower fluid
intelligence (ß = –0.74 SDs; 95% CI = –1.0, –0.48; P = 3.7 ×
10−8) and a decreased household income (ß = –1.98 SDs;
95% CI = –2.45, –1.51; P = 8.7 × 10−17) than 46,XX women
(Tables 1 and 2, Supplemental Table S3). Sixty-three percent
of women in the 47,XXX group had a household income less
than £18,000 per year, compared with 24% of 46,XX control
women. Women with 47,XXX were more likely to live alone
(OR = 2.07; 95% CI = 1.36, 3.12; P = 7 × 10−4) with 35.2%
(37/110) living alone compared with 19.8% of 46,XX women.
The women with 47,XXX also had a higher body mass index
(BMI) than the 46,XX women, by on average over 2 BMI units
(ß = 0.46 SDs; 95% CI = 0.26, 0.66; P = 6.3 × 10−6).
DISCUSSION
The availability of more than 244,000 adult women with SNP
array data in a population-based study enabled us to assess X
chromosome aneuploidy phenotypes without the potential
ascertainment biases of clinical presentation and with
sufficient statistical power to quantify phenotypic effects,
including adult-onset diseases. Previous studies have either
concentrated on clinically ascertained women, or prenatally
ascertained cases numbering in the tens and not followed up
into adulthood. While these studies have provided funda-
mental clinical descriptions of Turner and XXX syndrome,
they have not focused on the penetrance of the genetic
anomalies in the general population throughout the life
course. We identified 326 women in UK Biobank with whole
X chromosome dosage anomalies: 216 consistent with having
a 45,X or 45,X/46,XX mosaic karyotype and 110 with 47,XXX.
Prevalence of X chromosome aneuploidy
We detected a 45,X or 45,X/46,XX mosaic karyotype in 88/
100,000 women in UK Biobank. The published prevalence of
Turner syndrome is 40/100,000, but only 60% of those Turner
syndrome cases are caused by 45,X or 45,X/46,XX mosaicism,
the rest being due to other abnormalities such as deletions or
isoXq,15, 16 thus the prevalence of aneuploidy causing Turner
syndrome is around 24/100,000. This is nearly four times
lower than the prevalence we detected in UK Biobank,
suggesting that many cases go undiagnosed. Most series
report approximately 16% of aneuploidy cases being mosaic
45,X/46,XX, but in UK Biobank the proportion was 86%. The
prevalence of 45,X was only 12/100,000, lower than the
expected prevalence of approximately 20/100,000. This
difference is likely to be due in part to the UK Biobank
favoring healthy individuals, but also we may have classified
some 45,X cases as mosaic.
The prevalence of 47,XXX detected by SNP array in UK
Biobank was 45/100,000, substantially lower than the reported
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incidence of 100/100,000 live births. We observed an
association with IQ-related measures in women with 47,
XXX, and it is known that individuals with lower IQ were less
likely to participate in the study.17
Most women with 45,X/46,XX mosaicism detected
incidentally will not require clinical follow up
The most important implication of our data is that many
women with a 45,X cell line likely do not require currently
recommended interventions.18 The international clinical
practice guidelines do not readily differentiate mosaic from
nonmosaic 45,X, yet our data suggest that level of mosaicism
is an important clinical indicator of Turner syndrome features
and complications.18 In UK Biobank there were 186 women
who were mosaic for X chromosome loss. Surprisingly, the
phenotype in these women was unremarkable: while they
were slightly shorter on average, many of the women in this
category were of average height, with the tallest individual
being 182 cm, despite 20% of blood cells being 45,X
(Supplemental Fig. S3ah). This group of women went through
menarche and menopause at an average age, had an average
number of children, were not at increased risk of pregnancy
loss, and there was no evidence of increased risk of cardiac
complications. It is likely that women with mosaic 45,X/46,XX
seen in clinical practice are a more severe subgroup of the
population-wide group of women with this chromosome
anomaly.
Currently any women identified as having a 45,X cell line
not thought to be due to age-related loss, would be diagnosed
as having Turner syndrome and would be offered extensive
monitoring, particularly during pregnancy.18 While it is
recognized that mosaic cases may be less likely to have
abnormalities than nonmosaic 45,X Turner syndrome cases
they are still considered high risk with respect to cardiac
anomalies and hypertension during pregnancy for instance. In
young women, one of the main concerns will be the likelihood
of infertility associated with a diagnosis of Turner syndrome.
Our data suggest that in fact the presence of a 45,X cell line in
blood does not adversely affect reproductive lifespan or
fertility in most cases, as long as more than 20% of cells have
two X chromosomes.
Of the 326 women in UK Biobank with X chromosome
aneuploidy, 30 had a complete loss of one X chromosome,
and their features were consistent with a diagnosis of
Turner syndrome
Women with 45,X had a phenotype that was characteristic of
that reported for this chromosomal abnormality, i.e., short
stature and primary amenorrhea being the main features.
Cardiac abnormalities were not very common in this group,
but one had coronary artery disease and three had “heart
valve disease” and/or “stricture of the artery,” confirming
the need for continued screening programs. There were
no data available on physical characteristics, such as
neck webbing, which is a common physical feature in Turner
syndrome.
Women with 47,XXX are taller, have earlier menopause,
and are of below average cognitive ability
These findings are important because they suggest that
ascertainment bias has not dramatically influenced the
current consensus regarding the 47,XXX phenotype. Tradi-
tionally 47,XXX syndrome has been identified by cytogenetic
testing, which is costly, labor intensive, and requires fresh
tissue to culture dividing cells. Thus the majority of studies on
47,XXX have been on women tested for a clinical presentation
such as learning difficulties, or identified through prenatal
testing as an incidental finding. Cohorts of older women with
47,XXX are therefore uncommon. Primary ovarian insuffi-
ciency (POI) is often a reason for referral for 47,XXX
testing.19 Our data suggest that there is a genuine effect on
reproductive lifespan in women with 47,XXX. This effect
appears to be limited to the end of reproductive life however,
as these women had average menarche age, but went through
menopause on average more than 5 years earlier than women
with 46,XX, with 10 women meeting the criteria for POI, with
menopause before 40 years. The frequency of POI in 47,XXX
women is therefore 9%, approximately ten times that seen in
46,XX women. We found no evidence for an impact of 47,
XXX on reproductive function throughout life, as these
women had an average number of pregnancies and no
significant increase in pregnancy loss.
The UK Biobank women with 47,XXX were on average
5.3 cm taller than the 46,XX women. Adult height is
associated with puberty timing, with earlier puberty resulting
in shorter adult height. The 47,XXX effect on adult height is
however unlikely to be driven by later puberty timing, as
menarche age was not significantly different from the 46,XX
women. It is more likely that the increase in height is caused
by dosage-sensitive genes responsible for postpubertal growth.
The IQ of girls with 47,XXX is reported to be within the
normal range, but approximately 10–15 points below their
sibling average. Lower IQ is also reported in adult cases of 47,
XXX, along with psychosocial features, such as low self-
esteem, language difficulties, and increased prevalence of
psychiatric disorders.20 Few series of older women with 47,
XXX have been reported previously, but a study from
Denmark found reduced socioeconomic status in a series of
108 women with 47,XXX.21 In the UK Biobank study we
found a substantial reduction in fluid intelligence compared
with the 46,XX women. “Fluid intelligence” describes the
capacity to solve problems that require logic and reasoning
ability, independent of acquired knowledge. We observed an
increase in BMI in women with 47,XXX, that is not reported
as a typical feature of this chromosome abnormality, and may
be related to the observed lower IQ. There was also a
reduction in household income in women with 47,XXX. The
association with lower household income was not a
consequence of general lower socioeconomic status because
Townsend deprivation index was not significantly associated
with 47,XXX status. Ability to work and type of employment
taken by younger women with 47,XXX has been reported in
other studies, but with much smaller sample sizes. Thus the
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reduced IQ observed in adolescents with 47,XXX continues
into older age and appear to have a lifelong effect on income.
Limitations
The samples tested in this study were from peripheral blood
and may not reflect the level present in brain, ovary, or
heart, for example. Nonaneuploid causes of Turner
syndrome were not included in our analyses, although we
detected cases of apparent isoXq, and X chromosome
deletions, but we were unable to verify these cytogenetically.
Any cases with Y chromosome material were excluded as
sex mismatches.
Our study is biased in favor of healthier individuals with a
more benign phenotype.17 Biobank volunteers are more likely
to be female, have higher IQ, and be from a higher
socioeconomic group than the general population.17 Further-
more cases with a more severe phenotype that results in early
death will not be represented in this data set. Cases of X
chromosome aneuploidy with a severe phenotype may be
underrepresented in the Biobank cohort, but our study goes a
long way toward redressing the bias seen in many published
series of cases ascertained through clinical referrals .22
Validation
While we were not able to karyotype any of the samples from
UK Biobank, we did use two array platforms to test an
independent series of patients with various levels of 45,X
mosaicism and found close correlation between the methods.
Further validation came from finding 16 previously known
Turner syndrome cases in UK Biobank among the 30
individuals who we classified as nonmosaic 45,X with the
array dosage data. Three previously diagnosed cases of Turner
syndrome had a normal 46,XX SNP array profile; this may be
a sample mix-up, or a clinical case not confirmed by genetic
testing, or a more complex genetic abnormality not detected
by the array method. Indeed two additional previously known
Turner syndrome cases were suspected to be 46X,i(Xq), which
contribute to about 15% of published cases.15, 23 We adapted
our protocol to find additional nonaneuploid X chromosome
abnormalities and found a total of five suspected 46X,i(Xq)
and nine with X chromosome deletions, although we were not
able to validate with an independent technology. We are
confident that the cases we have identified do not include false
positives, but there may be X chromosome imbalances that we
did not detect.
Conclusions
We have assessed X chromosome aneuploidy phenotypes into
adulthood, without the ascertainment biases of clinical
presentation. X chromosome aneuploidy was not always
associated with an adverse phenotype: 45,X/46,XX mosaic
females had a normal reproductive lifespan and birth rate,
with no reported cardiovascular complications. This study
will inform the review of guidelines on the future manage-
ment of women with a 45,X/46,XX mosaic karyotype,
particularly as more individuals are obtaining genomic
information either as part of health-care assessments or
through direct-to-consumer genetic testing.
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